Long-Term Outcome of Catheter Ablation for Atrial Fibrillation in Patients With Apical Hypertrophic Cardiomyopathy

    loading  Checking for direct PDF access through Ovid



Atrial fibrillation (AF) is a common manifestation in cases of hypertrophic cardiomyopathy (HCM). Catheter ablation (CA) for AF in patients with asymmetric septal HCM (SeHCM) is selectively effective and often needs a repeat procedure. Apical HCM (ApHCM) has a better prognosis than SeHCM. However, the outcome of CA for AF in patients with ApHCM is unclear.

Methods and results:

Eighteen patients with ApHCM (ApHCM group) and 13 SeHCM patients (SeHCM group) underwent CA for AF. Ninety sex-, age-, and AF type-matched non-HCM patients who underwent CA for AF were selected as controls (5 controls for each ApHCM patient). During a median follow-up of 44.7 ± 30.8 months, 50% of the patients remained free from AF/atrial tachycardia (AT) in the ApHCM group. The ApHCM patients displayed enlarged left atrial (LA) diameter (47.1 ± 6.0 mm vs. 42.4 ± 5.5 mm, P = 0.006) and increased E/Ea ratio (13.5 ± 4.4 vs. 9.1 ± 3.1, P < 0.001) as compared to the control group. In contrast, the mean LA diameter and E/Ea ratio of the ApHCM group were not different than those of the SeHCM group. The overall freedom from AF/AT in the ApHCM group was significantly worse than in the control group (log rank P = 0.028), but there was no difference between the ApHCM and SeHCM groups (P = 0.831). High LA diameter index ≥25 mm/m2 (HR 12.8, 95% CI [1.2–142.1]; P = 0.037) was an independent predictor of AF/AT recurrence among patients with ApHCM.


Long-term outcome of CA for AF was worse in patients with ApHCM, as compared to controls, but was similar to patients with SeHCM.

Related Topics

    loading  Loading Related Articles